NYSE:ATNM

Actinium Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy ATNM

*Your capital is at risk

$1.16

-0.0600 (-4.92%)

At Close: Jun 03, 2026

Actinium Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -99.93. In total, the insiders bought 50K and sold 8M ATNM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-99.93
● Buy	50K shares
● Sell	8M shares
2% Buy Activity Negligible or No Correlation
Sell Signal High Confidence May 26, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -99.93. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (2% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Aug 18, 2025 Sell	Common Stock F-InKind	Seth Sandesh Chief Executive Officer	CEO / President	120 900 Value: $206.7K
Aug 18, 2025 Sell	Common Stock F-InKind	Seth Sandesh Chief Executive Officer	CEO / President	120 900 Value: $206.7K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Steinhart Richard I Director	Director	2 500 Value: $149.3K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Steinhart Richard I Director	Director	2 500 Value: $104.3K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Steinhart Richard I Director	Director	2 500 Value: $58.7K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Steinhart Richard I Director	Director	8 333 Value: $58.0K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Steinhart Richard I Director	Director	8 333 Value: $79.6K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Steinhart Richard I Director	Director	18 351 Value: $111.4K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Steinhart Richard I Director	Director	72 156 Value: $357.9K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Steinhart Richard I Director	Director	70 311 Value: $351.6K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Chell Jeffrey W. Director	Director	2 500 Value: $26.0K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Chell Jeffrey W. Director	Director	2 500 Value: $58.7K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Chell Jeffrey W. Director	Director	8 333 Value: $58.0K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Chell Jeffrey W. Director	Director	8 333 Value: $79.6K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Chell Jeffrey W. Director	Director	18 351 Value: $111.4K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Chell Jeffrey W. Director	Director	72 156 Value: $357.9K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Chell Jeffrey W. Director	Director	70 311 Value: $351.6K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Almenoff June Sherie Director	Director	50 000 Value: $85.5K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Nicholson, C. David Director	Director	2 500 Value: $149.3K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Nicholson, C. David Director	Director	2 500 Value: $104.3K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Nicholson, C. David Director	Director	2 500 Value: $58.7K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Nicholson, C. David Director	Director	8 333 Value: $58.0K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Nicholson, C. David Director	Director	8 333 Value: $79.6K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Nicholson, C. David Director	Director	18 351 Value: $111.4K
Mar 31, 2025 Sell	Stock Option (Right to Buy) D-Return	Nicholson, C. David Director	Director	72 156 Value: $357.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ACTINIUM PHARMACEUTICALS, INC

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19...

Read Full Profile Here